With awards ranging from $1.

AACN continues to offer annually the AACN-Sigma Theta Tau Critical Care Grant and AACN-Philips Medical Systems Outcomes Grant, up to $10,000 each; AACN-Edwards Lifesciences Nurse-Driven Clinical Practice Outcomes Grant, up to $10,000; and AACN Physio-Control Clinical Practice Grant, up to $1,500. All research grant applications open Sept. 1 and should be submitted by Nov on the web. 1. Principal investigators must be current AACN associates. For more information, including award requirements and supporting documents, visit or contact Linda Bell, AACN clinical practice professional, at 394-5995, ext.Adegbola, Ph.D., F.R.C.Route., Doudou Diop, M.D., Varsha Parulekar, M.Sc., Julie Chaumont, M.Sc., Lionel Martellet, M.A., Fatoumata Diallo, M.D., Olubukola T. Idoko, M.D., Yuxiao Tang, Ph.D., Brian D. Plikaytis, M.Sc., Prasad S. Kulkarni, M.D., Elisa Marchetti, Ph.D., F. Marc LaForce, M.D., and Marie-Pierre Preziosi, M.D., Ph.D.: Immunogenicity and Security of a Meningococcal A Conjugate Vaccine in Africans For greater than a century, major meningococcal meningitis epidemics have occurred every 10 to 12 years in what is called the African meningitis belt, which stretches from Senegal to Ethiopia.1-3 Nearly all these epidemics have already been due to group A Neisseria meningitidis, and incidence prices have been as high as 500 cases per 100,000 population, with the majority of cases occurring in persons between 1 and 29 years.4,5 In ’09 2009, more than 50,000 cases of group A meningococcal meningitis were reported in northern Nigeria.6 Because of the epidemic potential and high disease burden of group A meningococcal disease, controlling it is a public wellness priority in Africa.1-3,7 To handle this nagging problem, the World Health Company has emphasized case management and reactive emergency vaccination with polysaccharide vaccines.8,9 Although group A polysaccharide vaccine induces a good antibody response in persons between 1 and 29 years of age and has been shown to work in African field trials,10-12 reactive vaccination campaigns are costly and difficult logistically, plus they have not eliminated meningococcal epidemics.